sandostatin lar 10 mg
novartis pharma gmbh - germania - octreotidum - pulb. si solv. pt. susp. inj. - 10mg - hormoni hipotalamici hormoni anticrestere
sandostatin lar 20 mg
novartis pharma gmbh - germania - octreotidum - pulb. si solv. pt. susp. inj. - 20mg - hormoni hipotalamici hormoni anticrestere
sandostatin lar 30 mg
novartis pharma gmbh - germania - octreotidum - pulb. si solv. pt. susp. inj. - 30mg - hormoni hipotalamici hormoni anticrestere
sandostatin 100 micrograme/ml
novartis pharma gmbh - germania - octreotidum - sol. inj./perf. - 0,1mg/ml - hormoni hipotalamici hormoni anticrestere
icandra (previously vildagliptin / metformin hydrochloride novartis)
novartis europharm limited - vildagliptin, clorhidrat de metformină - diabetul zaharat, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 și 5. 1 pentru datele disponibile pe diferite combinații).
prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics
novartis vaccines and diagnostics s.r.l. - virusul gripei de suprafață (hemaglutinină și neuraminidază) de tulpina a / vietnam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vaccinuri - imunizarea activă împotriva subtipului h5n1 al virusului gripal a. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.
adakveo
novartis europharm limited - crizanlizumab - anemie, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.
sandostatin solutie injectabila 0,05 mg/ml
novartis pharma ag - octreotidum - solutie injectabila - 0,05 mg/ml
sandostatin solutie injectabila 0,1 mg/ml
novartis pharma ag - octreotidum - solutie injectabila - 0,1 mg/ml
sandostatin lar 10 mg pulbere şi solvent pentru suspensie injectabilă cu eliberare prelungită
novartis pharma ag - octreotidum - pulbere şi solvent pentru suspensie injectabilă cu eliberare prelungită - 10 mg